← All indications
Esophageal Squamous Cell Carcinoma
A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.
Drugs by status
Approved for this indication (1)
Phase 4 trials (4)
Phase 3 trials (27)
Phase 2 trials (69)
- icotinib
- metformin
- decitabine
- dacomitinib
- afatinib
- famitinib
- fulvestrant
- fruquintinib
- gemcitabine
- lapatinib
- cinobufacini
- epacadostat
- lenvatinib
- regorafenib
- trastuzumab
- pralatrexate
- pyrotinib
- ipilimumab
- sct200
- endostatin
- s-1
- sacituzumab govitecan
- celecoxib
- dalpiciclib
- belimumab
- sitravatinib
- temozolomide
- bevacizumab
- cetuximab
- itraconazole
- +39 more
Phase 1 trials (24)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (58)
- Amgen
- Roche
- AstraZeneca
- Merck
- AIO-Studien-gGmbH
- BeOne Medicines
- Biotech Pharmaceutical Co., Ltd.
- Innovent Biologics (Suzhou) Co. Ltd.
- Shanghai Henlius Biotech
- Shanghai Junshi Bioscience Co.,Ltd.
- National Cancer Institute (NCI)
- Huazhong University of Science and Technology
- Central South University
- Hebei University
- Huai'an First People's Hospital
- Nanjing Medical University
- NRG Oncology
- Shanxi Medical University
- Wuhan University
- Wuxi No. 4 People's Hospital
- University of Leipzig
- Capital Medical University
- Chinese University of Hong Kong
- Fudan University
- Fujian Medical University
- Japan Clinical Oncology Group
- Peking University
- Xiamen University
- Zhengzhou University
- The Second People's Hospital of Sichuan
- +28 more
Organization Involved with Phase 2 Indications (68)
- Spectrum Pharmaceuticals
- Seattle Genetics
- Shire
- Bristol-Myers Squibb
- Merck Serono
- Eli Lilly
- Hengrui Therapeutics, Inc.
- Innate Pharma
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Nang Kuang Pharmaceutical Co., Ltd.
- Onconova Therapeutics, Inc.
- PDS Biotechnology Corp.
- Sinocelltech Ltd.
- Sunshine Lake Pharma Co., Ltd.
- National Cancer Institute, France
- Shantou University Medical College
- Anhui Medical University
- Arizona State University
- BGI Group
- Blokhin's Russian Cancer Research Center
- China Three Gorges University, Yichang, China
- Cornell University
- Harvard University
- Dong-A University
- ECOG-ACRIN Cancer Research Group
- Federation Francophone de Cancerologie Digestive
- Temple University
- Guangzhou Medical University
- Instituto do Cancer do Estado de São Paulo
- Nanjing University
- +38 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (20)
- Maastricht University
- Rijnstate Hospital
- University of Groningen
- University of Toyama
- Utrecht University
- Zuyderland Medisch Centrum
- Deventer Ziekenhuis
- Leiden University
- Netherlands Cancer Institute
- Government of Korea
- Medisch Spectrum Twente
- Isala Clinics, Zwolle, The Netherlands
- Erasmus University Rotterdam
- Shiyan Taihe Hospital
- Ningbo No. 2 Hospital
- Radiotherapeutisch Instituut Friesland
- Elisabeth-TweeSteden Ziekenhuis
- Jiangsu Cancer Institute & Hospital
- Medical Center Leeuwarden
- Verbeeten Insituut Tilburg